Things To Do Today
Your Resource for Adverse Reactions and Drug Recalls
Bad Drug » Zoloft – Other Side Effects
Zoloft can cause a host of side effects, both common and serious. Some of the most common Zoloft side effects are nausea, which usually subsides after a few weeks of treatment, and sexual dysfunction, generally delayed orgasm in men and women. Tremor, headache, asthenia, rash and abnormal vision are also reasonably common Zoloft side effects.
One of the most widely-known serious side effects of Zoloft is the risk of increased suicidality in young adults below the age of 25. The FDA placed a black box warning on all antidepressants classified as SSRIs in 2007 that states the following:
Antidepressants increased the risk of suicidal thinking and behavior (suicidality) in short-term studies in children and adolescents with Major Depressive Disorder (MDD) and other psychiatric disorders. Anyone considering the use of Zoloft or any other antidepressant in a child or adolescent must balance this risk with the clinical need. Patients who are started on therapy should be observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Zoloft is not approved for use in pediatric patients except for patients with obsessive compulsive disorder (OCD).
Contacting this site does not constitute an attorney - client relationship. An attorney - client relationship can be created in a written agreement.
The information included on this site is for educational purposes only. It is not intended nor implied to be a substitute for professional medical advice. The reader should always consult his or her healthcare provider. Reading the information on this website does not create a physician-patient relationship.
Copyright © © 2024 deciBel Publishing. All rights reserved.
Sitemap | Call a Lawyer
Latest FDA News
Ocaliva (obeticholic acid) by Intercept Pharmaceuticals: Drug Safety Communication - Serious Liver Injury Being Observed in Patients without CirrhosisBased on its review of postmarket clinical trial data, the U.S. Food and Drug Administration (FDA) identified cases of serious liver injury among patients being treated for primary biliary cholangitis (PBC) with Ocaliva (obeticholic acid) who did not have cirrhosis of the liver.
Find us on Google+